20190513 PR IND TG4050 EN
Category: Press release
Transgene Announces Upcoming Investor Meetings
20190509 PR financial meetings Q2 19
Availability of Preparatory Documents for the Combined General Meeting of May 22, 2019
20190509MISE A DISPO AG – US
Transgene and AstraZeneca enter into a collaboration and exclusive license option agreement for innovative Invir.IO(TM) based armed oncolytic immunotherapies
20190502 – TG-AZ agreement – ENG
Transgene and BioInvent Extend their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors
20190326 PR BioInvent extension CDR US
Transgene: A positive 2018, moving ahead with a strong portfolio
20180320 FY RESULTS EN
Transgene secures a €20 Million Revolving Credit Facility with Natixis
20190318 PR Natixis loan EN
NEOVIVA project supporting the development of myvac® awarded a €5.2 million grant from Bpifrance’s “Investments for the Future” programme
20190313 – Neoviva – EN
Transgene to start clinical development of lead myvac® individualized immunotherapy, TG4050, in 2019, under its partnership with NEC
20190305-PR-NEC-Agreement-US-1
Transgene Completes Safety and Tolerability Assessment of TG4001 in Combination with Avelumab in Phase 1b Part of Trial in HPV-Positive Cancer Patients
20181220-Phase-1-TG4001-EN